
argenx (ARGX) Stock Forecast & Price Target
argenx (ARGX) Analyst Ratings
Bulls say
argenx is a rapidly growing company with strong financials, boasting a 14% sequential growth in net sales and an increase in new prescribers for VYVGART. The ongoing PFS launch and indication expansion will continue to drive growth, along with pipeline products such as ARGX-121, adimanebart, and empasiprubart, which have all shown positive results in clinical trials. Collaborations with top pharmaceutical companies also provide validation for argenx's antibody technology and potential for future success. With a strong pipeline and ongoing expansion efforts, argenx is well-positioned for long-term success in the biopharmaceutical industry.
Bears say
argenx is experiencing success with the expansion of their lead product, VYVGART, for the treatment of rare autoimmune diseases. However, risks to their price target and rating include potential failure in clinical, regulatory, or commercial aspects for this product or their pipeline, which could impact their overall financial performance in the future. It will be important to closely monitor the data presented at upcoming medical meetings and the outcome of the PDUFA date for seronegative gMG, as well as any potential setbacks in their other development efforts, in forming a comprehensive outlook on the company's future prospects.
This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.
argenx (ARGX) Analyst Forecast & Price Prediction
Start investing in argenx (ARGX)
Order type
Buy in
Order amount
Est. shares
0 shares